This clinical trial is focused on studying a condition known as Alpha-1 Antitrypsin Deficiency (AATD) Emphysema. This is a genetic disorder that can lead to lung problems, including emphysema, which is a type of chronic lung disease. The trial will use a treatment called INBRX-101, which is a concentrate for solution for infusion. This treatment contains a special protein called human alpha-1-proteinase inhibitor immunoglobulin G fusion protein, recombinant, designed to help manage the symptoms of AATD emphysema.

The purpose of the study is to evaluate the long-term safety and tolerability of INBRX-101 in adults with AATD emphysema. Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants over a period to observe any side effects and to assess how well the treatment works in managing the condition.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur during the treatment. They will also look at changes in lung density using a method called computed tomography (CT), which is a type of imaging that helps visualize the lungs. Additionally, the study will examine how the body processes the treatment and whether any antibodies, which are proteins made by the immune system, develop against INBRX-101. The study aims to provide valuable information on the safety and effectiveness of this treatment for people with AATD emphysema.